company background image
LSTA

Lisata Therapeutics NasdaqCM:LSTA Stock Report

Last Price

US$3.69

Market Cap

US$29.0m

7D

1.7%

1Y

-70.7%

Updated

02 Dec, 2022

Data

Company Financials +
LSTA fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

LSTA Stock Overview

Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue.

Lisata Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Lisata Therapeutics
Historical stock prices
Current Share PriceUS$3.69
52 Week HighUS$17.10
52 Week LowUS$3.50
Beta1.03
1 Month Change-12.77%
3 Month Change-51.71%
1 Year Change-70.72%
3 Year Change-90.54%
5 Year Change-93.35%
Change since IPO-100.00%

Recent News & Updates

We Think Caladrius Biosciences (NASDAQ:CLBS) Needs To Drive Business Growth Carefully

Sep 15
We Think Caladrius Biosciences (NASDAQ:CLBS) Needs To Drive Business Growth Carefully

Caladrius rallies on approval of merger, name change to Lisata Therapeutics

Sep 14

Recent updates

We Think Caladrius Biosciences (NASDAQ:CLBS) Needs To Drive Business Growth Carefully

Sep 15
We Think Caladrius Biosciences (NASDAQ:CLBS) Needs To Drive Business Growth Carefully

We Think Caladrius Biosciences (NASDAQ:CLBS) Needs To Drive Business Growth Carefully

May 02
We Think Caladrius Biosciences (NASDAQ:CLBS) Needs To Drive Business Growth Carefully

We're Keeping An Eye On Caladrius Biosciences' (NASDAQ:CLBS) Cash Burn Rate

Jan 05
We're Keeping An Eye On Caladrius Biosciences' (NASDAQ:CLBS) Cash Burn Rate

Companies Like Caladrius Biosciences (NASDAQ:CLBS) Are In A Position To Invest In Growth

May 09
Companies Like Caladrius Biosciences (NASDAQ:CLBS) Are In A Position To Invest In Growth

Here's Why We're Not Too Worried About Caladrius Biosciences' (NASDAQ:CLBS) Cash Burn Situation

Nov 30
Here's Why We're Not Too Worried About Caladrius Biosciences' (NASDAQ:CLBS) Cash Burn Situation

Shareholder Returns

LSTAUS BiotechsUS Market
7D1.7%2.7%1.4%
1Y-70.7%-10.3%-16.1%

Return vs Industry: LSTA underperformed the US Biotechs industry which returned -10.3% over the past year.

Return vs Market: LSTA underperformed the US Market which returned -16.1% over the past year.

Price Volatility

Is LSTA's price volatile compared to industry and market?
LSTA volatility
LSTA Average Weekly Movement10.5%
Biotechs Industry Average Movement11.2%
Market Average Movement7.4%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market3.3%

Stable Share Price: LSTA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: LSTA's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
198027Dave Mazzohttps://www.lisata.com

Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015.

Lisata Therapeutics, Inc. Fundamentals Summary

How do Lisata Therapeutics's earnings and revenue compare to its market cap?
LSTA fundamental statistics
Market CapUS$29.00m
Earnings (TTM)-US$55.03m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
LSTA income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$55.03m
Earnings-US$55.03m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-7.00
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did LSTA perform over the long term?

See historical performance and comparison